Iimveliso

Injongo yolu phononongo yayikukuthelekisa ukusebenza kwe-valproate ngokuchasene ne-haloperidol ekunciphiseni inqanaba lokuphazamiseka kwizigulane ezichaphazelekayo kwisebe elingxamisekileyo.Sabela izigulane ze-80 eziphazamisekileyo ukuba zifumane i-valproate ye-sodium emithanjeni (20 mg / kg) okanye i-haloperidol ye-intramuscular (5 mg / 1 ml).Ukuxhatshazwa kwalinganiswa kwisiseko kunye ne-30 min emva kwe-injection yokuqala usebenzisa i-Agitation-Calmness Evaluation Scale (ACES), i-Positive and Negative Syndrome Scale-Excited Component subscale, kunye ne-Agitated Behavior Scale.Kwizigulane ze-80 eziphathwe nge-valproate ye-sodium, i-dosage ye-± SD i-dosage yayiyi-1541.5 ± 286 mg (uluhlu lwe-940-2400).I-postintervention ye-ACES amanqaku ukusuka kwisiseko ukuya kwi-30 min emva kwe-injection yeziyobisi yi-4.73 (SD = 1.93) kwiqela le-valproate kunye ne-5.45 (SD = 2.09) kwiqela le-haloperidol (P = 0.028).Akukho ntlukwano ebalulekileyo ebonwe ngokwemiqathango yokutshintsha kwe-30 min emva kokungenelela kwezikali ezibini ezongezelelweyo zokuphazamiseka.Inxalenye enkulu yezigulane kwiqela le-haloperidol lafumana i-sedation enzulu (36.2%, P <0.001) kunye neempawu ze-extrapyramidal (8.7%, P = 0.007) xa kuthelekiswa neqela le-valproate (2.5% ye-sedation enzulu, akukho sigulane kwiimpawu ze-extrapyramidal).Iziphumo zophando zibonisa ukuba kwisimo seklinikhi ye-psychiatry engxamisekileyo, i-valproate ye-intravenous iyasebenza njenge-haloperidol ekunciphiseni ukuphazamiseka, kunye neprofayili engcono yokhuseleko.